|
WO2008027558A2
(en)
|
2006-08-31 |
2008-03-06 |
Codon Devices, Inc. |
Iterative nucleic acid assembly using activation of vector-encoded traits
|
|
CN103517990A
(zh)
|
2010-10-07 |
2014-01-15 |
通用医疗公司 |
癌症生物标志物
|
|
EP2637780B1
(en)
|
2010-11-12 |
2022-02-09 |
Gen9, Inc. |
Protein arrays and methods of using and making the same
|
|
EP3000883B8
(en)
|
2010-11-12 |
2018-02-28 |
Gen9, Inc. |
Methods and devices for nucleic acids synthesis
|
|
AR085533A1
(es)
|
2011-03-23 |
2013-10-09 |
Pioneer Hi Bred Int |
Metodos de produccion de un locus de rasgos transgenicos complejo
|
|
EP2732038B1
(en)
|
2011-07-15 |
2018-09-05 |
The General Hospital Corporation |
Methods of transcription activator like effector assembly
|
|
CA2853829C
(en)
|
2011-07-22 |
2023-09-26 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
IL280334B2
(en)
|
2011-08-26 |
2023-09-01 |
Gen9 Inc |
Preparations and methods for high-fidelity assembly of nucleic acids
|
|
JP2014531908A
(ja)
|
2011-10-14 |
2014-12-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
構造アッセンブリによる配列決定
|
|
ES2991004T3
(es)
|
2011-12-22 |
2024-12-02 |
Harvard College |
Métodos para la detección de analitos
|
|
GB201122458D0
(en)
|
2011-12-30 |
2012-02-08 |
Univ Wageningen |
Modified cascade ribonucleoproteins and uses thereof
|
|
WO2013139861A1
(en)
|
2012-03-20 |
2013-09-26 |
Luc Montagnier |
Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
|
|
US9150853B2
(en)
|
2012-03-21 |
2015-10-06 |
Gen9, Inc. |
Methods for screening proteins using DNA encoded chemical libraries as templates for enzyme catalysis
|
|
EP3543350B1
(en)
|
2012-04-24 |
2021-11-10 |
Gen9, Inc. |
Methods for sorting nucleic acids and multiplexed preparative in vitro cloning
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
GB2537000C
(en)
|
2012-05-25 |
2019-10-09 |
Univ California |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
US9890364B2
(en)
|
2012-05-29 |
2018-02-13 |
The General Hospital Corporation |
TAL-Tet1 fusion proteins and methods of use thereof
|
|
JP6509727B2
(ja)
|
2012-06-25 |
2019-05-15 |
ギンゴー バイオワークス， インコーポレイテッド |
核酸アセンブリおよび高処理シークエンシングのための方法
|
|
EP2906602B1
(en)
|
2012-10-12 |
2019-01-16 |
The General Hospital Corporation |
Transcription activator-like effector (tale) - lysine-specific demethylase 1 (lsd1) fusion proteins
|
|
CA2891347C
(en)
|
2012-12-06 |
2018-02-27 |
Sigma-Aldrich Co. Llc |
Crispr-based genome modification and regulation
|
|
EP2931899A1
(en)
|
2012-12-12 |
2015-10-21 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
|
|
WO2014093709A1
(en)
|
2012-12-12 |
2014-06-19 |
The Broad Institute, Inc. |
Methods, models, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
|
|
IL239317B
(en)
|
2012-12-12 |
2022-07-01 |
Broad Inst Inc |
Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
|
|
US10544405B2
(en)
|
2013-01-16 |
2020-01-28 |
Emory University |
Cas9-nucleic acid complexes and uses related thereto
|
|
US10676749B2
(en)
|
2013-02-07 |
2020-06-09 |
The General Hospital Corporation |
Tale transcriptional activators
|
|
EP3578666A1
(en)
|
2013-03-12 |
2019-12-11 |
President and Fellows of Harvard College |
Method of generating a three-dimensional nucleic acid containing matrix
|
|
AU2014235794A1
(en)
|
2013-03-14 |
2015-10-22 |
Caribou Biosciences, Inc. |
Compositions and methods of nucleic acid-targeting nucleic acids
|
|
US10760064B2
(en)
|
2013-03-15 |
2020-09-01 |
The General Hospital Corporation |
RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
|
|
WO2014204578A1
(en)
|
2013-06-21 |
2014-12-24 |
The General Hospital Corporation |
Using rna-guided foki nucleases (rfns) to increase specificity for rna-guided genome editing
|
|
KR102874079B1
(ko)
|
2013-03-15 |
2025-10-22 |
더 제너럴 하스피탈 코포레이션 |
Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
CN115261411A
(zh)
*
|
2013-04-04 |
2022-11-01 |
哈佛学院校长同事会 |
利用CRISPR/Cas系统的基因组编辑的治疗性用途
|
|
WO2014197568A2
(en)
|
2013-06-04 |
2014-12-11 |
President And Fellows Of Harvard College |
Rna-guideded transcriptional regulation
|
|
US20140356956A1
(en)
*
|
2013-06-04 |
2014-12-04 |
President And Fellows Of Harvard College |
RNA-Guided Transcriptional Regulation
|
|
EP4435110A3
(en)
*
|
2013-06-05 |
2025-01-01 |
Duke University |
Rna-guided gene editing and gene regulation
|
|
CN105793425B
(zh)
|
2013-06-17 |
2021-10-26 |
布罗德研究所有限公司 |
使用病毒组分靶向障碍和疾病的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
WO2014204725A1
(en)
|
2013-06-17 |
2014-12-24 |
The Broad Institute Inc. |
Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
|
|
EP3011033B1
(en)
|
2013-06-17 |
2020-02-19 |
The Broad Institute, Inc. |
Functional genomics using crispr-cas systems, compositions methods, screens and applications thereof
|
|
AU2014281028B2
(en)
|
2013-06-17 |
2020-09-10 |
Massachusetts Institute Of Technology |
Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
|
|
CN106062197A
(zh)
|
2013-06-17 |
2016-10-26 |
布罗德研究所有限公司 |
用于序列操纵的串联指导系统、方法和组合物的递送、工程化和优化
|
|
WO2015006498A2
(en)
|
2013-07-09 |
2015-01-15 |
President And Fellows Of Harvard College |
Therapeutic uses of genome editing with crispr/cas systems
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
WO2015021426A1
(en)
*
|
2013-08-09 |
2015-02-12 |
Sage Labs, Inc. |
A crispr/cas system-based novel fusion protein and its application in genome editing
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
MX2016002306A
(es)
*
|
2013-08-22 |
2016-07-08 |
Du Pont |
Promotor u6 de polimerasa iii de soja y metodos de uso.
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9228207B2
(en)
|
2013-09-06 |
2016-01-05 |
President And Fellows Of Harvard College |
Switchable gRNAs comprising aptamers
|
|
US9388430B2
(en)
*
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
ES2844174T3
(es)
|
2013-09-18 |
2021-07-21 |
Kymab Ltd |
Métodos, células y organismos
|
|
WO2015066119A1
(en)
|
2013-10-30 |
2015-05-07 |
North Carolina State University |
Compositions and methods related to a type-ii crispr-cas system in lactobacillus buchneri
|
|
CN111218447B
(zh)
|
2013-11-07 |
2024-10-11 |
爱迪塔斯医药有限公司 |
使用统治型gRNA的CRISPR相关方法和组合物
|
|
WO2015089486A2
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Systems, methods and compositions for sequence manipulation with optimized functional crispr-cas systems
|
|
EP3080266B1
(en)
*
|
2013-12-12 |
2021-02-03 |
The Regents of The University of California |
Methods and compositions for modifying a single stranded target nucleic acid
|
|
MX374530B
(es)
|
2013-12-12 |
2025-03-06 |
Broad Inst Inc |
Suministro, uso y aplicaciones terapeuticas de los sistemas y composiciones crispr-cas para actuar sobre hbv y trastornos y enfermedades virales.
|
|
WO2015089364A1
(en)
|
2013-12-12 |
2015-06-18 |
The Broad Institute Inc. |
Crystal structure of a crispr-cas system, and uses thereof
|
|
EP3080257A1
(en)
|
2013-12-12 |
2016-10-19 |
The Broad Institute Inc. |
Compositions and methods of use of crispr-cas systems in nucleotide repeat disorders
|
|
EP3080259B1
(en)
|
2013-12-12 |
2023-02-01 |
The Broad Institute, Inc. |
Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
|
|
CN118813621A
(zh)
|
2013-12-12 |
2024-10-22 |
布罗德研究所有限公司 |
用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用
|
|
US20150166982A1
(en)
*
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting pi3k point mutations
|
|
JP6721508B2
(ja)
|
2013-12-26 |
2020-07-15 |
ザ ジェネラル ホスピタル コーポレイション |
多重ガイドｒｎａ
|
|
US10787654B2
(en)
|
2014-01-24 |
2020-09-29 |
North Carolina State University |
Methods and compositions for sequence guiding Cas9 targeting
|
|
WO2015123339A1
(en)
|
2014-02-11 |
2015-08-20 |
The Regents Of The University Of Colorado, A Body Corporate |
Crispr enabled multiplexed genome engineering
|
|
EP3114227B1
(en)
|
2014-03-05 |
2021-07-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
|
|
US11339437B2
(en)
|
2014-03-10 |
2022-05-24 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US9938521B2
(en)
|
2014-03-10 |
2018-04-10 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating leber's congenital amaurosis 10 (LCA10)
|
|
US11141493B2
(en)
|
2014-03-10 |
2021-10-12 |
Editas Medicine, Inc. |
Compositions and methods for treating CEP290-associated disease
|
|
US11242525B2
(en)
|
2014-03-26 |
2022-02-08 |
Editas Medicine, Inc. |
CRISPR/CAS-related methods and compositions for treating sickle cell disease
|
|
WO2015153780A1
(en)
|
2014-04-02 |
2015-10-08 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating primary open angle glaucoma
|
|
CN106460003A
(zh)
|
2014-04-08 |
2017-02-22 |
北卡罗来纳州立大学 |
用于使用crispr相关基因rna引导阻遏转录的方法和组合物
|
|
US10066241B2
(en)
|
2014-05-30 |
2018-09-04 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods of delivering treatments for latent viral infections
|
|
IL286474B2
(en)
|
2014-06-23 |
2023-11-01 |
Massachusetts Gen Hospital |
Genome-wide random identification of DSBS assessed by sequencing (guide-sequence)
|
|
US20150376587A1
(en)
*
|
2014-06-25 |
2015-12-31 |
Caribou Biosciences, Inc. |
RNA Modification to Engineer Cas9 Activity
|
|
EP3760208B1
(en)
|
2014-06-25 |
2024-05-29 |
The General Hospital Corporation |
Targeting human satellite ii (hsatii)
|
|
US20170198268A1
(en)
*
|
2014-07-09 |
2017-07-13 |
Gen9, Inc. |
Compositions and Methods for Site-Directed DNA Nicking and Cleaving
|
|
AU2015288157A1
(en)
|
2014-07-11 |
2017-01-19 |
E. I. Du Pont De Nemours And Company |
Compositions and methods for producing plants resistant to glyphosate herbicide
|
|
WO2016007839A1
(en)
|
2014-07-11 |
2016-01-14 |
President And Fellows Of Harvard College |
Methods for high-throughput labelling and detection of biological features in situ using microscopy
|
|
EP3177718B1
(en)
|
2014-07-30 |
2022-03-16 |
President and Fellows of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
US9932566B2
(en)
|
2014-08-07 |
2018-04-03 |
Agilent Technologies, Inc. |
CIS-blocked guide RNA
|
|
WO2016033298A1
(en)
|
2014-08-28 |
2016-03-03 |
North Carolina State University |
Novel cas9 proteins and guiding features for dna targeting and genome editing
|
|
WO2016040030A1
(en)
|
2014-09-12 |
2016-03-17 |
E. I. Du Pont De Nemours And Company |
Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
|
|
WO2016049258A2
(en)
*
|
2014-09-25 |
2016-03-31 |
The Broad Institute Inc. |
Functional screening with optimized functional crispr-cas systems
|
|
WO2016054106A1
(en)
*
|
2014-09-29 |
2016-04-07 |
The Regents Of The University Of California |
SCAFFOLD RNAs
|
|
EP3204496A1
(en)
*
|
2014-10-10 |
2017-08-16 |
Editas Medicine, Inc. |
Compositions and methods for promoting homology directed repair
|
|
GB201418965D0
(cg-RX-API-DMAC7.html)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
|
EP3215623A4
(en)
|
2014-11-06 |
2018-09-26 |
President and Fellows of Harvard College |
Cells lacking b2m surface expression and methods for allogeneic administration of such cells
|
|
WO2016073990A2
(en)
|
2014-11-07 |
2016-05-12 |
Editas Medicine, Inc. |
Methods for improving crispr/cas-mediated genome-editing
|
|
JP6621820B2
(ja)
*
|
2014-11-14 |
2019-12-18 |
インスティチュート フォー ベーシック サイエンスＩｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂａｓｉｃ Ｓｃｉｅｎｃｅ |
ゲノムでプログラマブルヌクレアーゼの非標的位置を検出する方法
|
|
US11352666B2
(en)
|
2014-11-14 |
2022-06-07 |
Institute For Basic Science |
Method for detecting off-target sites of programmable nucleases in a genome
|
|
CN104531633A
(zh)
*
|
2014-11-18 |
2015-04-22 |
李云英 |
Cas9-scForkI融合蛋白及其应用
|
|
EP3222728B1
(en)
|
2014-11-19 |
2021-07-14 |
Institute for Basic Science |
Method for regulating gene expression using cas9 protein expressed from two vectors
|
|
KR102763527B1
(ko)
|
2014-12-03 |
2025-02-05 |
애질런트 테크놀로지스, 인크. |
화학적 변형을 갖는 가이드 rna
|
|
US10975392B2
(en)
|
2014-12-05 |
2021-04-13 |
Abcam Plc |
Site-directed CRISPR/recombinase compositions and methods of integrating transgenes
|
|
WO2016094679A1
(en)
|
2014-12-10 |
2016-06-16 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
EP3230452B1
(en)
*
|
2014-12-12 |
2025-06-11 |
The Broad Institute, Inc. |
Dead guides for crispr transcription factors
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
US20180179523A1
(en)
*
|
2014-12-18 |
2018-06-28 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
EP3786296A1
(en)
*
|
2014-12-18 |
2021-03-03 |
Integrated Dna Technologies, Inc. |
Crispr-based compositions and methods of use
|
|
US10190106B2
(en)
*
|
2014-12-22 |
2019-01-29 |
Univesity Of Massachusetts |
Cas9-DNA targeting unit chimeras
|
|
AU2015369725A1
(en)
|
2014-12-24 |
2017-06-29 |
Massachusetts Institute Of Technology |
CRISPR having or associated with destabilization domains
|
|
US11208638B2
(en)
|
2015-01-12 |
2021-12-28 |
The Regents Of The University Of California |
Heterodimeric Cas9 and methods of use thereof
|
|
EP3250689B1
(en)
*
|
2015-01-28 |
2020-11-04 |
The Regents of The University of California |
Methods and compositions for labeling a single-stranded target nucleic acid
|
|
SI3250691T1
(sl)
*
|
2015-01-28 |
2023-10-30 |
Caribou Biosciences, Inc. |
Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo
|
|
WO2016130600A2
(en)
|
2015-02-09 |
2016-08-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
JP6785235B2
(ja)
*
|
2015-02-18 |
2020-11-18 |
アイオワ・ステイト・ユニバーシティ・リサーチ・ファウンデイション・インコーポレイテッドＩｏｗａ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ， Ｉｎｃ． |
高いタンパク質含有量及びストレスに対する抵抗性のためのｎｆ−ｙｃ４プロモーター中の転写リプレッサー結合部位の修飾
|
|
WO2016141224A1
(en)
|
2015-03-03 |
2016-09-09 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases with altered pam specificity
|
|
BR112017017260A2
(pt)
|
2015-03-27 |
2018-04-17 |
Du Pont |
construções de dna, vetor, célula, plantas, semente, método de expressão de rna e método de modificação de local alvo
|
|
CA2981715A1
(en)
|
2015-04-06 |
2016-10-13 |
The Board Of Trustees Of The Leland Stanford Junior University |
Chemically modified guide rnas for crispr/cas-mediated gene regulation
|
|
CA2982966C
(en)
|
2015-04-24 |
2024-02-20 |
Editas Medicine, Inc. |
Evaluation of cas9 molecule/guide rna molecule complexes
|
|
CA2988854A1
(en)
|
2015-05-08 |
2016-11-17 |
President And Fellows Of Harvard College |
Universal donor stem cells and related methods
|
|
JP7030522B2
(ja)
|
2015-05-11 |
2022-03-07 |
エディタス・メディシン、インコーポレイテッド |
幹細胞における遺伝子編集のための最適化ｃｒｉｓｐｒ／ｃａｓ９システムおよび方法
|
|
EA201792663A1
(ru)
|
2015-05-29 |
2018-04-30 |
Норт Каролина Стейт Юниверсити |
Способы скрининга бактерий, архей, водорослей и дрожжей с использованием нуклеиновых кислот crispr
|
|
US20160346360A1
(en)
|
2015-05-29 |
2016-12-01 |
Agenovir Corporation |
Compositions and methods for cell targeted hpv treatment
|
|
US10117911B2
(en)
|
2015-05-29 |
2018-11-06 |
Agenovir Corporation |
Compositions and methods to treat herpes simplex virus infections
|
|
EP3303634B1
(en)
|
2015-06-03 |
2023-08-30 |
The Regents of The University of California |
Cas9 variants and methods of use thereof
|
|
US20180296537A1
(en)
|
2015-06-05 |
2018-10-18 |
Novartis Ag |
Methods and compositions for diagnosing, treating, and monitoring treatment of shank3 deficiency associated disorders
|
|
KR102796744B1
(ko)
|
2015-06-09 |
2025-04-15 |
에디타스 메디신, 인코포레이티드 |
이식의 개선을 위한 crispr/cas-관련 방법 및 조성물
|
|
EP3726218B1
(en)
*
|
2015-06-10 |
2023-08-09 |
Firmenich Sa |
Cell lines for screening odorant and aroma receptors
|
|
WO2016201399A1
(en)
|
2015-06-12 |
2016-12-15 |
Lonza Walkersville, Inc. |
Methods for nuclear reprogramming using synthetic transcription factors
|
|
US11155823B2
(en)
|
2015-06-15 |
2021-10-26 |
North Carolina State University |
Methods and compositions for efficient delivery of nucleic acids and RNA-based antimicrobials
|
|
WO2016205759A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
|
|
WO2016205613A1
(en)
|
2015-06-18 |
2016-12-22 |
The Broad Institute Inc. |
Crispr enzyme mutations reducing off-target effects
|
|
US11279928B2
(en)
*
|
2015-06-29 |
2022-03-22 |
Massachusetts Institute Of Technology |
Compositions comprising nucleic acids and methods of using the same
|
|
CA2990699A1
(en)
|
2015-06-29 |
2017-01-05 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and modified single crispr rna and uses thereof
|
|
EP3322804B1
(en)
|
2015-07-15 |
2021-09-01 |
Rutgers, The State University of New Jersey |
Nuclease-independent targeted gene editing platform and uses thereof
|
|
WO2017015637A1
(en)
*
|
2015-07-22 |
2017-01-26 |
Duke University |
High-throughput screening of regulatory element function with epigenome editing technologies
|
|
GB2592821B
(en)
|
2015-07-31 |
2022-01-12 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017024047A1
(en)
*
|
2015-08-03 |
2017-02-09 |
Emendobio Inc. |
Compositions and methods for increasing nuclease induced recombination rate in cells
|
|
WO2017023974A1
(en)
*
|
2015-08-03 |
2017-02-09 |
President And Fellows Of Harvard College |
Cas9 genome editing and transcriptional regulation
|
|
EP4345454A3
(en)
|
2015-08-25 |
2024-07-17 |
Duke University |
Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases
|
|
EP3341477B1
(en)
*
|
2015-08-28 |
2022-03-23 |
The General Hospital Corporation |
Engineered crispr-cas9 nucleases
|
|
US9926546B2
(en)
|
2015-08-28 |
2018-03-27 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
US9512446B1
(en)
|
2015-08-28 |
2016-12-06 |
The General Hospital Corporation |
Engineered CRISPR-Cas9 nucleases
|
|
CN107922949A
(zh)
*
|
2015-08-31 |
2018-04-17 |
安捷伦科技有限公司 |
用于通过同源重组的基于crispr/cas的基因组编辑的化合物和方法
|
|
WO2017044776A1
(en)
*
|
2015-09-10 |
2017-03-16 |
Texas Tech University System |
Single-guide rna (sgrna) with improved knockout efficiency
|
|
AU2016319110B2
(en)
*
|
2015-09-11 |
2022-01-27 |
The General Hospital Corporation |
Full interrogation of nuclease DSBs and sequencing (FIND-seq)
|
|
US11667911B2
(en)
|
2015-09-24 |
2023-06-06 |
Editas Medicine, Inc. |
Use of exonucleases to improve CRISPR/CAS-mediated genome editing
|
|
EP3356533A1
(en)
|
2015-09-28 |
2018-08-08 |
North Carolina State University |
Methods and compositions for sequence specific antimicrobials
|
|
WO2017059313A1
(en)
|
2015-09-30 |
2017-04-06 |
The General Hospital Corporation |
Comprehensive in vitro reporting of cleavage events by sequencing (circle-seq)
|
|
EP3359674A4
(en)
|
2015-10-06 |
2019-03-13 |
Institute for Basic Science |
PROCESS FOR THE PRODUCTION OF ALL PLANTS FROM PROTOPLASTS
|
|
WO2017066497A2
(en)
|
2015-10-13 |
2017-04-20 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
DK3350327T3
(en)
|
2015-10-23 |
2019-01-21 |
Caribou Biosciences Inc |
CONSTRUCTED CRISPR CLASS-2-NUCLEIC ACID TARGETING-NUCLEIC ACID
|
|
SG11201803173VA
(en)
|
2015-10-23 |
2018-05-30 |
Harvard College |
Nucleobase editors and uses thereof
|
|
HK1252878A1
(zh)
|
2015-11-03 |
2019-06-06 |
President And Fellows Of Harvard College |
用於含有基质的三维核酸的体积成像的方法和设备
|
|
US11566052B2
(en)
|
2015-11-11 |
2023-01-31 |
Lonza Ltd. |
CRISPR-associated (Cas) proteins with reduced immunogenicity
|
|
JP7054678B2
(ja)
|
2015-11-20 |
2022-04-14 |
ワシントン・ユニバーシティ |
ゲノムｄｎａ断片の標的化された精製のための調製用電気泳動方法
|
|
US10612044B2
(en)
|
2015-11-25 |
2020-04-07 |
National University Corporation Gunma University |
DNA methylation editing kit and DNA methylation editing method
|
|
EP4644567A2
(en)
|
2015-11-30 |
2025-11-05 |
Duke University |
Therapeutic targets for the correction of the human dystrophin gene by gene editing and methods of use
|
|
US11345931B2
(en)
|
2015-12-14 |
2022-05-31 |
President And Fellows Of Harvard College |
Cas discrimination using tuned guide RNA
|
|
US11542466B2
(en)
|
2015-12-22 |
2023-01-03 |
North Carolina State University |
Methods and compositions for delivery of CRISPR based antimicrobials
|
|
US20190010495A1
(en)
*
|
2015-12-28 |
2019-01-10 |
Novartis Ag |
Compositions and methods for the treatment of hemoglobinopathies
|
|
SG11201805792PA
(en)
|
2016-01-11 |
2018-08-30 |
Univ Leland Stanford Junior |
Chimeric proteins and methods of regulating gene expression
|
|
KR102808969B1
(ko)
|
2016-01-11 |
2025-05-15 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
키메라 단백질 및 면역요법 방법
|
|
US11845933B2
(en)
|
2016-02-03 |
2023-12-19 |
Massachusetts Institute Of Technology |
Structure-guided chemical modification of guide RNA and its applications
|
|
CN114196746A
(zh)
|
2016-02-10 |
2022-03-18 |
密歇根大学董事会 |
核酸的检测
|
|
WO2017143071A1
(en)
|
2016-02-18 |
2017-08-24 |
The Regents Of The University Of California |
Methods and compositions for gene editing in stem cells
|
|
US10538750B2
(en)
|
2016-02-29 |
2020-01-21 |
Agilent Technologies, Inc. |
Methods and compositions for blocking off-target nucleic acids from cleavage by CRISPR proteins
|
|
IL316539A
(en)
*
|
2016-03-15 |
2024-12-01 |
Rnaissance Ag Llc |
Methods and compositions for the enhanced production of double-stranded RNA
|
|
EP3429567B1
(en)
|
2016-03-16 |
2024-01-10 |
The J. David Gladstone Institutes |
Methods and compositions for treating obesity and/or diabetes and for identifying candidate treatment agents
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
EP3433364A1
(en)
|
2016-03-25 |
2019-01-30 |
Editas Medicine, Inc. |
Systems and methods for treating alpha 1-antitrypsin (a1at) deficiency
|
|
WO2017165826A1
(en)
|
2016-03-25 |
2017-09-28 |
Editas Medicine, Inc. |
Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
|
|
CN106701765A
(zh)
*
|
2016-04-11 |
2017-05-24 |
广东赤萌医疗科技有限公司 |
用于hiv感染治疗的多核苷酸及其制备药物应用
|
|
US20190127713A1
(en)
|
2016-04-13 |
2019-05-02 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
EP4047092B1
(en)
|
2016-04-13 |
2025-07-30 |
Editas Medicine, Inc. |
Cas9 fusion molecules, gene editing systems, and methods of use thereof
|
|
JP7259182B2
(ja)
|
2016-04-25 |
2023-04-18 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ｉｎ ｓｉｔｕ分子検出のためのハイブリダイゼーション連鎖反応法
|
|
CN107326046A
(zh)
*
|
2016-04-28 |
2017-11-07 |
上海邦耀生物科技有限公司 |
一种提高外源基因同源重组效率的方法
|
|
NZ747857A
(en)
|
2016-05-20 |
2023-01-27 |
Regeneron Pharma |
Methods for breaking immunological tolerance using multiple guide rnas
|
|
US20190100732A1
(en)
*
|
2016-06-02 |
2019-04-04 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Assay for the removal of methyl-cytosine residues from dna
|
|
PL3272867T3
(pl)
|
2016-06-02 |
2020-01-31 |
Sigma-Aldrich Co. Llc |
Wykorzystanie programowalnych białek wiążących dna w celu wzmocnienia celowanej modyfikacji genomu
|
|
US10767175B2
(en)
|
2016-06-08 |
2020-09-08 |
Agilent Technologies, Inc. |
High specificity genome editing using chemically modified guide RNAs
|
|
CN109312386B
(zh)
*
|
2016-06-15 |
2022-10-25 |
株式会社图尔金 |
使用中靶靶标和脱靶靶标的多重靶标系统筛选靶特异性核酸酶的方法及其用途
|
|
US10017760B2
(en)
|
2016-06-24 |
2018-07-10 |
Inscripta, Inc. |
Methods for generating barcoded combinatorial libraries
|
|
EP3474849B1
(en)
*
|
2016-06-27 |
2025-05-21 |
The Broad Institute, Inc. |
Compositions and methods for detecting and treating diabetes
|
|
CN109477130B
(zh)
*
|
2016-07-01 |
2022-08-30 |
微软技术许可有限责任公司 |
通过迭代dna编辑的存储
|
|
US20180004537A1
(en)
|
2016-07-01 |
2018-01-04 |
Microsoft Technology Licensing, Llc |
Molecular State Machines
|
|
US11359234B2
(en)
|
2016-07-01 |
2022-06-14 |
Microsoft Technology Licensing, Llc |
Barcoding sequences for identification of gene expression
|
|
WO2018010516A1
(zh)
*
|
2016-07-13 |
2018-01-18 |
陈奇涵 |
一种基因组dna特异性编辑方法和应用
|
|
CN109863143B
(zh)
|
2016-07-13 |
2021-10-15 |
威泰克斯制药公司 |
提高基因组编辑效率的方法、组合物和试剂盒
|
|
WO2018017754A1
(en)
|
2016-07-19 |
2018-01-25 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
CN109790527A
(zh)
*
|
2016-07-26 |
2019-05-21 |
通用医疗公司 |
普氏菌属和弗朗西斯氏菌属的CRISPR1(Cpf1)的变体
|
|
WO2018021855A1
(ko)
*
|
2016-07-28 |
2018-02-01 |
기초과학연구원 |
Cas9 단백질 및 가이드 RNA를 포함하는 안질환 치료용 약학 조성물
|
|
SG11201901305YA
(en)
|
2016-07-29 |
2019-03-28 |
Regeneron Pharma |
Mice comprising mutations resulting in expression of c-truncated fibrillin-1
|
|
BR112019001887A2
(pt)
|
2016-08-02 |
2019-07-09 |
Editas Medicine Inc |
composições e métodos para o tratamento de doença associada a cep290
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
|
EP3498834A4
(en)
|
2016-08-10 |
2020-06-17 |
Genahead Bio, Inc. |
METHOD FOR MODIFYING A TARGET SITE IN THE GENOME OF A EUKARYOTE CELL, AND METHOD FOR DETECTING THE PRESENCE OR ABSENCE OF A NUCLEIC ACID SEQUENCE TO BE DETECTED AT A TARGET SITE
|
|
CA3033939A1
(en)
*
|
2016-08-19 |
2018-02-22 |
Toolgen Incorporated |
Artificially engineered angiogenesis regulatory system
|
|
US11434476B2
(en)
*
|
2016-08-19 |
2022-09-06 |
Whitehead Institute For Biomedical Research |
Methods of editing DNA methylation
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
CA3034882A1
(en)
|
2016-08-24 |
2018-03-01 |
Sangamo Therapeutics, Inc. |
Regulation of gene expression using engineered nucleases
|
|
BR112019003327A2
(pt)
|
2016-08-24 |
2019-07-02 |
Sangamo Therapeutics, Inc. |
nucleases manipuladas de alvo específico
|
|
CN109890962A
(zh)
|
2016-09-07 |
2019-06-14 |
旗舰创业股份有限公司 |
用于调节基因表达的方法和组合物
|
|
WO2018048194A1
(ko)
*
|
2016-09-07 |
2018-03-15 |
울산대학교 산학협력단 |
dCas9 단백질 및 표적 핵산 서열에 결합하는 gRNA를 이용한 핵산 검출의 민감도 및 특이도 향상용 조성물 및 방법
|
|
KR20230170126A
(ko)
|
2016-09-30 |
2023-12-18 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
|
|
CN107880132B
(zh)
*
|
2016-09-30 |
2022-06-17 |
北京大学 |
一种融合蛋白及使用其进行同源重组的方法
|
|
US10669539B2
(en)
|
2016-10-06 |
2020-06-02 |
Pioneer Biolabs, Llc |
Methods and compositions for generating CRISPR guide RNA libraries
|
|
CN110462034A
(zh)
|
2016-10-07 |
2019-11-15 |
综合Dna技术公司 |
化脓链球菌cas9突变基因和由其编码的多肽
|
|
US11242542B2
(en)
|
2016-10-07 |
2022-02-08 |
Integrated Dna Technologies, Inc. |
S. pyogenes Cas9 mutant genes and polypeptides encoded by same
|
|
CN110290813A
(zh)
*
|
2016-10-14 |
2019-09-27 |
通用医疗公司 |
表观遗传学调控的位点特异性核酸酶
|
|
WO2018071868A1
(en)
|
2016-10-14 |
2018-04-19 |
President And Fellows Of Harvard College |
Aav delivery of nucleobase editors
|
|
CA3041068A1
(en)
|
2016-10-18 |
2018-04-26 |
Regents Of The University Of Minnesota |
Tumor infiltrating lymphocytes and methods of therapy
|
|
EP3535396A1
(en)
|
2016-11-01 |
2019-09-11 |
Novartis AG |
Methods and compositions for enhancing gene editing
|
|
US20180282722A1
(en)
*
|
2016-11-21 |
2018-10-04 |
Massachusetts Institute Of Technology |
Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
|
|
KR20250021632A
(ko)
|
2016-11-22 |
2025-02-13 |
인티그레이티드 디엔에이 테크놀로지스 아이엔씨. |
Crispr/cpf1 시스템 및 방법
|
|
WO2018107028A1
(en)
*
|
2016-12-08 |
2018-06-14 |
Intellia Therapeutics, Inc. |
Modified guide rnas
|
|
US11293022B2
(en)
|
2016-12-12 |
2022-04-05 |
Integrated Dna Technologies, Inc. |
Genome editing enhancement
|
|
EP3551218A4
(en)
|
2016-12-12 |
2020-12-09 |
Whitehead Institute for Biomedical Research |
REGULATION OF TRANSCRIPTION THANKS TO CTCF LOOP ANCHORS
|
|
KR20240172763A
(ko)
|
2016-12-14 |
2024-12-10 |
리간달 인코포레이티드 |
핵산 및/또는 단백질 적재물 전달을 위한 조성물 및 방법
|
|
EP3555297A1
(en)
|
2016-12-19 |
2019-10-23 |
Editas Medicine, Inc. |
Assessing nuclease cleavage
|
|
KR102551664B1
(ko)
*
|
2016-12-22 |
2023-07-05 |
인텔리아 테라퓨틱스, 인크. |
알파-1 항트립신 결핍을 치료하기 위한 조성물 및 방법
|
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
|
US20190382751A1
(en)
*
|
2016-12-28 |
2019-12-19 |
Ionis Pharmaceuticals, Inc. |
Modified crispr rna and uses thereof
|
|
US12065666B2
(en)
|
2017-01-05 |
2024-08-20 |
Rutgers, The State University Of New Jersey |
Targeted gene editing platform independent of DNA double strand break and uses thereof
|
|
JP7229923B2
(ja)
|
2017-01-06 |
2023-02-28 |
エディタス・メディシン、インコーポレイテッド |
ヌクレアーゼ切断を評価する方法
|
|
US11873496B2
(en)
|
2017-01-09 |
2024-01-16 |
Whitehead Institute For Biomedical Research |
Methods of altering gene expression by perturbing transcription factor multimers that structure regulatory loops
|
|
EP3572525A4
(en)
*
|
2017-01-17 |
2020-09-30 |
Institute for Basic Science |
PROCEDURE FOR IDENTIFYING AN OFF-TARGET BASIC EDITING SITE BY BREAKING A SINGLE DNA STRAND
|
|
CA3049980A1
(en)
|
2017-01-23 |
2018-07-26 |
Regeneron Pharmaceuticals, Inc. |
Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
WO2018148511A1
(en)
*
|
2017-02-10 |
2018-08-16 |
Zymergen Inc. |
A modular universal plasmid design strategy for the assembly and editing of multiple dna constructs for multiple hosts
|
|
WO2018154096A1
(en)
|
2017-02-24 |
2018-08-30 |
Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin |
Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated rasal,1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including rasal1 in a subject
|
|
WO2018165309A1
(en)
|
2017-03-08 |
2018-09-13 |
The Regents Of The University Of Michigan |
Analyte detection
|
|
US12390514B2
(en)
|
2017-03-09 |
2025-08-19 |
President And Fellows Of Harvard College |
Cancer vaccine
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
KR20240116572A
(ko)
|
2017-03-23 |
2024-07-29 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
|
|
CN108660161B
(zh)
*
|
2017-03-31 |
2023-05-09 |
中国科学院脑科学与智能技术卓越创新中心 |
基于CRISPR/Cas9技术的制备无嵌合基因敲除动物的方法
|
|
EP3607308A1
(en)
*
|
2017-04-07 |
2020-02-12 |
Sage Science, Inc. |
Systems and methods for detection of genetic structural variation using integrated electrophoretic dna purification
|
|
WO2018195540A1
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Inducible, tunable, and multiplex human gene regulation using crispr-cpf1
|
|
WO2018195545A2
(en)
|
2017-04-21 |
2018-10-25 |
The General Hospital Corporation |
Variants of cpf1 (cas12a) with altered pam specificity
|
|
EP3615672A1
(en)
|
2017-04-28 |
2020-03-04 |
Editas Medicine, Inc. |
Methods and systems for analyzing guide rna molecules
|
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
CA3063449A1
(en)
|
2017-05-25 |
2018-11-29 |
The General Hospital Corporation |
Using split deaminases to limit unwanted off-target base editor deamination
|
|
CA3065938A1
(en)
|
2017-06-05 |
2018-12-13 |
Regeneron Pharmaceuticals, Inc. |
B4galt1 variants and uses thereof
|
|
CN108977442B
(zh)
*
|
2017-06-05 |
2023-01-06 |
广州市锐博生物科技有限公司 |
用于dna编辑的系统及其应用
|
|
US10428319B2
(en)
|
2017-06-09 |
2019-10-01 |
Editas Medicine, Inc. |
Engineered Cas9 nucleases
|
|
KR102634727B1
(ko)
|
2017-06-14 |
2024-02-07 |
위스콘신 얼럼나이 리서어치 화운데이션 |
변형된 가이드 rna, crispr-리보뉴클레오프로테인 복합체 및 사용 방법
|
|
MX2019015188A
(es)
|
2017-06-15 |
2020-08-03 |
Univ California |
Inserciones de adn no virales orientadas.
|
|
US9982279B1
(en)
|
2017-06-23 |
2018-05-29 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
US10011849B1
(en)
|
2017-06-23 |
2018-07-03 |
Inscripta, Inc. |
Nucleic acid-guided nucleases
|
|
CN111511375A
(zh)
|
2017-06-30 |
2020-08-07 |
因提玛生物科学公司 |
用于基因治疗的腺相关病毒载体
|
|
EP3645721A1
(en)
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
CN111183226A
(zh)
|
2017-07-11 |
2020-05-19 |
西格马-奥尔德里奇有限责任公司 |
使用核小体相互作用蛋白结构域来增强靶向基因组修饰
|
|
US11866726B2
(en)
|
2017-07-14 |
2024-01-09 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
EP3658573A1
(en)
|
2017-07-28 |
2020-06-03 |
President and Fellows of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace)
|
|
US20190032156A1
(en)
|
2017-07-31 |
2019-01-31 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
|
|
BR112020001364A2
(pt)
|
2017-07-31 |
2020-08-11 |
Regeneron Pharmaceuticals, Inc. |
métodos para testar e modificar a capacidade de uma crispr/cas nuclease.
|
|
WO2019028023A2
(en)
|
2017-07-31 |
2019-02-07 |
Regeneron Pharmaceuticals, Inc. |
METHODS AND COMPOSITIONS FOR EVALUATING CRISPR / CAS MEDIATED DISRUPTION OR EXCISION AND CRISPR / CAS INDUCED RECOMBINATION USING IN VIVO EXOGENIC DONOR NUCLEIC ACID
|
|
US11897920B2
(en)
|
2017-08-04 |
2024-02-13 |
Peking University |
Tale RVD specifically recognizing DNA base modified by methylation and application thereof
|
|
CN111278983A
(zh)
|
2017-08-08 |
2020-06-12 |
北京大学 |
基因敲除方法
|
|
JP7581046B2
(ja)
|
2017-08-23 |
2024-11-12 |
ザ ジェネラル ホスピタル コーポレイション |
変更されたＰＡＭ特異性を有する遺伝子操作されたＣＲＩＳＰＲ－Ｃａｓ９ヌクレアーゼ
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
EP4276185A3
(en)
|
2017-09-29 |
2024-02-21 |
Regeneron Pharmaceuticals, Inc. |
Rodents comprising a humanized ttr locus and methods of use
|
|
US11725228B2
(en)
|
2017-10-11 |
2023-08-15 |
The General Hospital Corporation |
Methods for detecting site-specific and spurious genomic deamination induced by base editing technologies
|
|
AU2018352592C1
(en)
|
2017-10-16 |
2025-09-25 |
Beam Therapeutics, Inc. |
Uses of adenosine base editors
|
|
CN107602707B
(zh)
*
|
2017-10-17 |
2021-04-23 |
湖北大学 |
一种特异性调节枯草芽孢杆菌外源基因表达的dcas9-ω融合蛋白及其应用
|
|
MX2020004325A
(es)
|
2017-10-27 |
2020-11-09 |
Univ California |
Reemplazo dirigido de receptores de células t endógenos.
|
|
EP3704251A2
(en)
*
|
2017-11-01 |
2020-09-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
|
US20210180053A1
(en)
|
2017-11-01 |
2021-06-17 |
Novartis Ag |
Synthetic rnas and methods of use
|
|
CN111448313A
(zh)
|
2017-11-16 |
2020-07-24 |
阿斯利康(瑞典)有限公司 |
用于改善基于Cas9的敲入策略的有效性的组合物和方法
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
KR102098915B1
(ko)
|
2017-12-22 |
2020-04-09 |
(주)지플러스 생명과학 |
키메라 게놈 조작 분자 및 방법
|
|
CN109504711A
(zh)
*
|
2018-02-14 |
2019-03-22 |
复旦大学 |
基于CRISPR/cas9和过氧化物酶APEX2系统识别分析特异性基因组位点相互作用DNA的方法
|
|
EP3755798A4
(en)
|
2018-02-19 |
2022-04-06 |
Yale University |
PHOSPHOPEPTIDE-ENCODING OLIGONUCLEOTIDE LIBRARIES AND METHODS FOR DETECTING PHOSPHORYLATION-DEPENDENT MOLECULAR INTERACTIONS
|
|
CN112020554B
(zh)
|
2018-02-23 |
2024-10-22 |
先锋国际良种公司 |
新颖cas9直系同源物
|
|
WO2019178426A1
(en)
|
2018-03-14 |
2019-09-19 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
WO2019183123A1
(en)
|
2018-03-19 |
2019-09-26 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
AU2019247490A1
(en)
|
2018-04-06 |
2020-10-22 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
|
WO2019204378A1
(en)
|
2018-04-17 |
2019-10-24 |
The General Hospital Corporation |
Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
|
|
EP3781705A4
(en)
|
2018-04-19 |
2022-01-26 |
The Regents of the University of California |
COMPOSITIONS AND METHODS OF GENE EDIT
|
|
WO2019213430A1
(en)
*
|
2018-05-03 |
2019-11-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for nicking target dna sequences
|
|
CN108588123A
(zh)
*
|
2018-05-07 |
2018-09-28 |
南京医科大学 |
CRISPR/Cas9载体组合在制备基因敲除猪的血液制品中的应用
|
|
CA3100019A1
(en)
|
2018-05-11 |
2019-11-14 |
Beam Therapeutics Inc. |
Methods of substituting pathogenic amino acids using programmable base editor systems
|
|
WO2019222545A1
(en)
|
2018-05-16 |
2019-11-21 |
Synthego Corporation |
Methods and systems for guide rna design and use
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
EP3575396A1
(en)
*
|
2018-06-01 |
2019-12-04 |
Algentech SAS |
Gene targeting
|
|
CN110592141B
(zh)
*
|
2018-06-13 |
2023-07-07 |
中国科学院上海有机化学研究所 |
用于调控基因编辑效率的化合物及其应用
|
|
US12227776B2
(en)
|
2018-06-13 |
2025-02-18 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
US10227576B1
(en)
|
2018-06-13 |
2019-03-12 |
Caribou Biosciences, Inc. |
Engineered cascade components and cascade complexes
|
|
CA3104856A1
(en)
|
2018-06-29 |
2020-01-02 |
Editas Medicine, Inc. |
Synthetic guide molecules, compositions and methods relating thereto
|
|
CA3105658A1
(en)
|
2018-07-13 |
2020-01-16 |
The Regents Of The University Of California |
Retrotransposon-based delivery vehicle and methods of use thereof
|
|
WO2020086144A2
(en)
|
2018-08-15 |
2020-04-30 |
Zymergen Inc. |
APPLICATIONS OF CRISPRi IN HIGH THROUGHPUT METABOLIC ENGINEERING
|
|
WO2020041456A1
(en)
|
2018-08-22 |
2020-02-27 |
The Regents Of The University Of California |
Variant type v crispr/cas effector polypeptides and methods of use thereof
|
|
CN112867792A
(zh)
|
2018-08-23 |
2021-05-28 |
桑格摩生物治疗股份有限公司 |
工程化靶特异性碱基编辑器
|
|
CN112654702B
(zh)
|
2018-09-07 |
2025-05-13 |
阿斯利康(瑞典)有限公司 |
改进的核酸酶的组合物和方法
|
|
US12203123B2
(en)
|
2018-10-01 |
2025-01-21 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for screening for variant cells
|
|
EP3861120A4
(en)
|
2018-10-01 |
2023-08-16 |
North Carolina State University |
Recombinant type i crispr-cas system
|
|
US12264313B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for genome modification and alteration of expression
|
|
US12264330B2
(en)
|
2018-10-01 |
2025-04-01 |
North Carolina State University |
Recombinant type I CRISPR-Cas system and uses thereof for killing target cells
|
|
WO2020076976A1
(en)
|
2018-10-10 |
2020-04-16 |
Readcoor, Inc. |
Three-dimensional spatial molecular indexing
|
|
US11407995B1
(en)
|
2018-10-26 |
2022-08-09 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
US11434477B1
(en)
|
2018-11-02 |
2022-09-06 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
US11739320B2
(en)
|
2018-11-05 |
2023-08-29 |
Wisconsin Alumni Research Foundation |
Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
|
|
AU2019374883A1
(en)
|
2018-11-09 |
2021-05-20 |
Inari Agriculture Technology, Inc. |
RNA-guided nucleases and DNA binding proteins
|
|
CA3117228A1
(en)
|
2018-12-14 |
2020-06-18 |
Pioneer Hi-Bred International, Inc. |
Novel crispr-cas systems for genome editing
|
|
CA3120799A1
(en)
|
2018-12-20 |
2020-06-25 |
Regeneron Pharmaceuticals, Inc. |
Nuclease-mediated repeat expansion
|
|
EP3911746A1
(en)
|
2019-01-14 |
2021-11-24 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and kits for generating and selecting a variant of a binding protein with increased binding affinity and/or specificity
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US11946040B2
(en)
|
2019-02-04 |
2024-04-02 |
The General Hospital Corporation |
Adenine DNA base editor variants with reduced off-target RNA editing
|
|
WO2020163856A1
(en)
|
2019-02-10 |
2020-08-13 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Modified mitochondrion and methods of use thereof
|
|
WO2020181101A1
(en)
|
2019-03-07 |
2020-09-10 |
The Regents Of The University Of California |
Crispr-cas effector polypeptides and methods of use thereof
|
|
KR102695765B1
(ko)
|
2019-03-18 |
2024-08-20 |
리제너론 파마슈티칼스 인코포레이티드 |
타우 시딩 또는 응집의 유전적 변형제를 식별하기 위한 CRISPR/Cas 스크리닝 플랫폼
|
|
CA3127814C
(en)
|
2019-03-18 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas dropout screening platform to reveal genetic vulnerabilities associated with tau aggregation
|
|
GB2601617B
(en)
|
2019-03-19 |
2024-02-21 |
Broad Inst Inc |
Methods and compositions for editing nucleotide sequences
|
|
BR112021019512A2
(pt)
|
2019-04-03 |
2022-02-15 |
Regeneron Pharma |
Métodos para inserir uma sequência de codificação de proteína de ligação ao antígeno e para tratar ou efetuar a profilaxia de uma doença em um animal, animal, célula, genoma, ácido nucleico doador exógeno, gene de porto seguro, e, agente de nuclease ou um ou mais ácidos nucleicos
|
|
CA3133359C
(en)
|
2019-04-04 |
2023-04-11 |
Regeneron Pharmaceuticals, Inc. |
Methods for scarless introduction of targeted modifications into targeting vectors
|
|
IL286905B2
(en)
|
2019-04-04 |
2024-06-01 |
Regeneron Pharma |
Non-human animals containing the human coagulation factor 12 locus
|
|
CN113748205A
(zh)
|
2019-04-12 |
2021-12-03 |
阿斯利康(瑞典)有限公司 |
用于改进的基因编辑的组合物和方法
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
US11622547B2
(en)
|
2019-06-07 |
2023-04-11 |
Regeneran Pharmaceuticals, Inc. |
Genetically modified mouse that expresses human albumin
|
|
ES3034102T3
(en)
|
2019-06-14 |
2025-08-13 |
Regeneron Pharma |
Models of tauopathy
|
|
EP3783104A1
(en)
*
|
2019-08-20 |
2021-02-24 |
Kemijski Institut |
Coiled-coil mediated tethering of crispr-cas and exonucleases for enhanced genome editing
|
|
JP2022548031A
(ja)
|
2019-09-13 |
2022-11-16 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
脂質ナノ粒子によって送達されるｃｒｉｓｐｒ／ｃａｓシステムを使用する動物における転写調節
|
|
JP2022548399A
(ja)
|
2019-09-23 |
2022-11-18 |
オメガ セラピューティクス， インコーポレイテッド |
肝細胞核因子４－アルファ（ＨＮＦ４α）遺伝子発現をモジュレートするための組成物および方法
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP3812472B1
(en)
|
2019-10-21 |
2022-11-23 |
Albert-Ludwigs-Universität Freiburg |
A truly unbiased in vitro assay to profile off-target activity of one or more target-specific programmable nucleases in cells (abnoba-seq)
|
|
US11331333B2
(en)
|
2019-11-08 |
2022-05-17 |
Georg-August-Universität Göttingen Stiftung Öffentichen Rechts, Universitätsmadizin |
Treatment of aberrant fibroblast proliferation
|
|
AU2020379046B2
(en)
|
2019-11-08 |
2025-03-13 |
Regeneron Pharmaceuticals, Inc. |
CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy
|
|
US20230042198A1
(en)
*
|
2019-11-25 |
2023-02-09 |
La Jolla Institute For Immunology |
Methods and Compositions for Modulationg Heterochromatin Dysfunction, Genomic Instability, and Associate Conditions
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
MX2022006950A
(es)
|
2019-12-11 |
2022-11-07 |
Intellia Therapeutics Inc |
Arn guía modificados para edición de genes.
|
|
CN111088357B
(zh)
*
|
2019-12-31 |
2022-09-20 |
深圳大学 |
针对escc的肿瘤标志物及其应用
|
|
EP4093863A4
(en)
|
2020-01-24 |
2024-04-10 |
The General Hospital Corporation |
CRISPR-CAS ENZYMES WITH ENHANCED ON-TARGET ACTIVITY
|
|
WO2021151073A2
(en)
|
2020-01-24 |
2021-07-29 |
The General Hospital Corporation |
Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants
|
|
CA3169991A1
(en)
|
2020-02-12 |
2021-08-19 |
Massachusetts Eye And Ear Infirmary |
Haplotype-based treatment of rp1 associated retinal degenerations
|
|
US11965161B2
(en)
|
2020-03-04 |
2024-04-23 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for sensitization of tumor cells to immune therapy
|
|
WO2021178924A1
(en)
*
|
2020-03-05 |
2021-09-10 |
Board Of Regents Of The University Of Nebraska |
Crispr/cas9 system for multistrain hiv-1 treatment
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
WO2021207710A2
(en)
*
|
2020-04-09 |
2021-10-14 |
Verve Therapeutics, Inc. |
Base editing of angptl3 and methods of using same for treatment of disease
|
|
JP2023524976A
(ja)
*
|
2020-05-04 |
2023-06-14 |
エディタス・メディシン、インコーポレイテッド |
必須遺伝子ノックインによる選択
|
|
EP4146797A1
(en)
|
2020-05-06 |
2023-03-15 |
Orchard Therapeutics (Europe) Limited |
Treatment for neurodegenerative diseases
|
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
|
JP2023526007A
(ja)
|
2020-05-13 |
2023-06-20 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
β－ヘモグロビン異常症の処置のための塩基編集アプローチ
|
|
WO2021246165A1
(ja)
*
|
2020-06-03 |
2021-12-09 |
国立大学法人広島大学 |
Ｏａｓｉｓ遺伝子の脱メチル化のための核酸及びそれを用いた脱メチル化方法
|
|
MX2022015284A
(es)
*
|
2020-06-05 |
2023-01-19 |
Univ California |
Composiciones y metodos para la edicion del epigenoma.
|
|
US20230235315A1
(en)
|
2020-07-10 |
2023-07-27 |
Horizon Discovery Limited |
Method for producing genetically modified cells
|
|
CA3188895A1
(en)
|
2020-08-11 |
2022-02-17 |
Rami Aqeilan |
Method for the treatment of wwox associated diseases
|
|
US20220049303A1
(en)
|
2020-08-17 |
2022-02-17 |
Readcoor, Llc |
Methods and systems for spatial mapping of genetic variants
|
|
KR102674574B1
(ko)
*
|
2020-09-02 |
2024-06-13 |
한국과학기술연구원 |
Cas9을 위한 신규 tracrRNA 시스템
|
|
US20240016855A1
(en)
|
2020-10-13 |
2024-01-18 |
Centre National De La Recherche Scientifique (Cnrs) |
Targeted-antibacterial-plasmids combining conjugation and crispr/cas systems and uses thereof
|
|
CN112430622A
(zh)
*
|
2020-10-26 |
2021-03-02 |
扬州大学 |
一种FokI和dCpf1融合蛋白表达载体及其介导的定点基因编辑方法
|
|
RU2762831C1
(ru)
*
|
2020-10-26 |
2021-12-23 |
Федеральное государственное бюджетное научное учреждение "Всероссийский научно-исследовательский институт сельскохозяйственной биотехнологии" (ФГБНУ ВНИИСБ) |
Молекула рнк-проводника для геномного редактирования протомоторной области гена vrn-a1 однодольных зерновых с применением системы crispr/cas9
|
|
US20240002839A1
(en)
|
2020-12-02 |
2024-01-04 |
Decibel Therapeutics, Inc. |
Crispr sam biosensor cell lines and methods of use thereof
|
|
KR20220082186A
(ko)
|
2020-12-10 |
2022-06-17 |
한세준 |
유,무선 충전이 가능한 보조배터리형 uv-led살균기
|
|
EP4274893B1
(en)
|
2021-01-05 |
2025-01-01 |
Revvity Discovery Limited |
Method for producing genetically modified cells
|
|
EP4288541A1
(en)
|
2021-02-05 |
2023-12-13 |
Christiana Care Gene Editing Institute, Inc. |
Methods of and compositions for reducing gene expression and/or activity
|
|
WO2022180153A1
(en)
|
2021-02-25 |
2022-09-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Allele-specific genome editing of the nr2e3 mutation g56r
|
|
KR102882704B1
(ko)
|
2021-03-03 |
2025-11-12 |
중앙대학교 산학협력단 |
CRISPR/Cas9 시스템을 이용한 유전체 단일염기 편집 방법 및 이의 용도
|
|
CN113846019B
(zh)
*
|
2021-03-05 |
2023-08-01 |
海南师范大学 |
一种海洋微拟球藻靶向表观基因组遗传调控方法
|
|
EP4095243A1
(en)
|
2021-05-25 |
2022-11-30 |
European Molecular Biology Laboratory |
System for hybridization-based precision genome cleavage and editing, and uses thereof
|
|
US20240384246A1
(en)
|
2021-05-27 |
2024-11-21 |
Astrazeneca Ab |
Ca s9 effector proteins with enhanced stability
|
|
WO2022261292A1
(en)
|
2021-06-10 |
2022-12-15 |
Intellia Therapeutics, Inc. |
Modified guide rnas comprising an internal linker for gene editing
|
|
WO2023010135A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
CA3229450A1
(en)
|
2021-08-20 |
2023-02-23 |
Wisconsin Alumni Research Foundation |
Nonviral generation of genome edited chimeric antigen receptor t cells
|
|
JP2024534945A
(ja)
|
2021-09-10 |
2024-09-26 |
アジレント・テクノロジーズ・インク |
化学修飾を有するプライム編集のためのガイドｒｎａ
|
|
EP4596697A3
(en)
|
2021-09-28 |
2025-08-27 |
Acrigen Biosciences |
Compositions and methods for nucleic acid modifications
|
|
WO2023052366A1
(en)
|
2021-09-28 |
2023-04-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-hemoglobinopathies
|
|
EP4408996A2
(en)
|
2021-09-30 |
2024-08-07 |
Astrazeneca AB |
Use of inhibitors to increase efficiency of crispr/cas insertions
|
|
WO2023064928A2
(en)
|
2021-10-14 |
2023-04-20 |
Arsenal Biosciences, Inc. |
Immune cells having co-expressed shrnas and logic gate systems
|
|
AU2022368907A1
(en)
|
2021-10-20 |
2024-05-02 |
University Of Copenhagen |
Rejuvenation treatment of age-related white matter loss
|
|
US20240415980A1
(en)
|
2021-10-28 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
|
CA3237303A1
(en)
|
2021-11-03 |
2023-05-11 |
Intellia Therapeutics, Inc. |
Polynucleotides, compositions, and methods for genome editing
|
|
WO2023099591A1
(en)
|
2021-12-01 |
2023-06-08 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for increasing fetal hemoglobin content by editing the +55-kb region of the erythroid-specific bcl11a enhancer
|
|
WO2023108047A1
(en)
|
2021-12-08 |
2023-06-15 |
Regeneron Pharmaceuticals, Inc. |
Mutant myocilin disease model and uses thereof
|
|
US20230279442A1
(en)
|
2021-12-15 |
2023-09-07 |
Versitech Limited |
Engineered cas9-nucleases and method of use thereof
|
|
WO2023137471A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
CA3247927A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
US20250113795A1
(en)
*
|
2022-01-20 |
2025-04-10 |
Inari Agriculture Technology, Inc. |
Improved soybean explant preparation and transformation
|
|
WO2023141602A2
(en)
|
2022-01-21 |
2023-07-27 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
EP4469574A1
(en)
|
2022-01-25 |
2024-12-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Base editing approaches for the treatment of beta-thalassemia
|
|
WO2023150623A2
(en)
|
2022-02-02 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease
|
|
US20250152677A1
(en)
|
2022-02-14 |
2025-05-15 |
Institut National de la Santé et de la Recherche Médicale |
Treatment of liver cancers by disrupting the beta-catenin/tcf-4 binding site located upstreatm of meg3 in the dlk1/dio3 locus
|
|
JP2025514304A
(ja)
|
2022-04-29 |
2025-05-02 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定
|
|
CA3256953A1
(en)
|
2022-05-09 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
VECTORS AND METHODS FOR IN VIVO ANTIBODY PRODUCTION
|
|
EP4522647A1
(en)
|
2022-05-10 |
2025-03-19 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the cd39 (cag>tag) mutation in patients suffering from beta-thalassemia
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
WO2023235726A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr interference therapeutics for c9orf72 repeat expansion disease
|
|
KR20250044484A
(ko)
|
2022-06-24 |
2025-03-31 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통해 저밀도 지단백질을 감소시키기 위한 조성물, 시스템, 및 방법
|
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
|
CN120344660A
(zh)
|
2022-07-18 |
2025-07-18 |
雷纳嘉德医疗管理公司 |
基因编辑组分、系统和使用方法
|
|
WO2024018056A1
(en)
|
2022-07-22 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for correcting the ivs2-1 (g>a) mutation in patients suffering from βeta-thalassemia
|
|
EP4561636A1
(en)
|
2022-07-29 |
2025-06-04 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
|
|
CN120435557A
(zh)
|
2022-08-19 |
2025-08-05 |
图恩疗法股份有限公司 |
通过靶向基因阻遏调节乙型肝炎病毒的组合物、系统和方法
|
|
WO2024044723A1
(en)
|
2022-08-25 |
2024-02-29 |
Renagade Therapeutics Management Inc. |
Engineered retrons and methods of use
|
|
WO2024047247A1
(en)
|
2022-09-02 |
2024-03-07 |
Institut National de la Santé et de la Recherche Médicale |
Base editing approaches for the treatment of amyotrophic lateral sclerosis
|
|
EP4590821A2
(en)
|
2022-09-19 |
2025-07-30 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
WO2024073606A1
(en)
|
2022-09-28 |
2024-04-04 |
Regeneron Pharmaceuticals, Inc. |
Antibody resistant modified receptors to enhance cell-based therapies
|
|
JP2025534904A
(ja)
|
2022-10-21 |
2025-10-21 |
キージーン ナムローゼ フェンノートシャップ |
修飾ｒｎａによる植物細胞へのｒｎａトランスフェクション
|
|
US20240182561A1
(en)
|
2022-11-04 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
|
|
EP4619438A2
(en)
|
2022-11-14 |
2025-09-24 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
|
|
CN115820603B
(zh)
*
|
2022-11-15 |
2024-07-05 |
吉林大学 |
一种基于dCasRx-NSUN6单基因特异性M5C修饰编辑方法
|
|
WO2024121354A1
(en)
|
2022-12-08 |
2024-06-13 |
Keygene N.V. |
Duplex sequencing with covalently closed dna ends
|
|
TW202440931A
(zh)
*
|
2022-12-23 |
2024-10-16 |
大陸商益杰立科（上海）生物科技有限公司 |
融合物及其用途
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
EP4662313A1
(en)
|
2023-02-06 |
2025-12-17 |
Institut National de la Santé et de la Recherche Médicale |
Enrichment of genetically modified hematopoietic stem cells through multiplex base editing
|
|
CN116376975B
(zh)
*
|
2023-02-27 |
2024-05-14 |
中国科学院脑科学与智能技术卓越创新中心 |
激活异染色质基因的方法及应用
|
|
TW202436622A
(zh)
|
2023-03-06 |
2024-09-16 |
美商英特利亞醫療公司 |
用於ｂ型肝炎病毒（ｈｂｖ）基因體編輯之組合物及方法
|
|
CN118684781A
(zh)
*
|
2023-03-21 |
2024-09-24 |
深圳赫兹生命科学技术有限公司 |
GnRH-VLP重组去势疫苗及其制备方法
|
|
CN121127605A
(zh)
|
2023-03-29 |
2025-12-12 |
阿斯利康(瑞典)有限公司 |
使用抑制剂来提高CRISPR/Cas插入的效率
|
|
WO2024209000A1
(en)
|
2023-04-04 |
2024-10-10 |
Keygene N.V. |
Linkers for duplex sequencing
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
AU2024309884A1
(en)
|
2023-06-30 |
2025-12-18 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for increasing homology-directed repair
|
|
WO2025017030A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Prime editing of the -200 region in the hbg1 and/or hbg2 promoter for increasing fetal hemoglobin content in a eukaryotic cell
|
|
WO2025017033A1
(en)
|
2023-07-17 |
2025-01-23 |
Institut National de la Santé et de la Recherche Médicale |
Prime editing of the -115 region in the hbg1 and/or hbg2 promoter for increasing fetal hemoglobin content in a eukaryotic cell
|
|
KR20250016657A
(ko)
*
|
2023-07-21 |
2025-02-04 |
한국화학연구원 |
dxCas9 및 CRP 유도체를 포함하는, 표적 유전자 발현 조절 시스템 및 이의 제조방법
|
|
US20250049896A1
(en)
|
2023-07-28 |
2025-02-13 |
Regeneron Pharmaceuticals, Inc. |
Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency
|
|
WO2025029654A2
(en)
|
2023-07-28 |
2025-02-06 |
Regeneron Pharmaceuticals, Inc. |
Use of bgh-sv40l tandem polya to enhance transgene expression during unidirectional gene insertion
|
|
AR133385A1
(es)
|
2023-07-28 |
2025-09-24 |
Regeneron Pharma |
Inserción anti-tfr:gaa y anti-cd63:gaa para el tratamiento de la enfermedad de pompe
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025038648A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025038642A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying cd70
|
|
WO2025038646A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Cd70 car-t compositions and methods for cell-based therapy
|
|
WO2025038637A1
(en)
|
2023-08-14 |
2025-02-20 |
Intellia Therapeutics, Inc. |
Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
|
|
WO2025049524A1
(en)
|
2023-08-28 |
2025-03-06 |
Regeneron Pharmaceuticals, Inc. |
Cxcr4 antibody-resistant modified receptors
|
|
WO2025049959A2
(en)
|
2023-09-01 |
2025-03-06 |
Renagade Therapeutics Management Inc. |
Gene editing systems, compositions, and methods for treatment of vexas syndrome
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025064408A1
(en)
|
2023-09-18 |
2025-03-27 |
The Broad Institute, Inc. |
Compositions and methods for treating cardiovascular disease
|
|
WO2025081042A1
(en)
|
2023-10-12 |
2025-04-17 |
Renagade Therapeutics Management Inc. |
Nickase-retron template-based precision editing system and methods of use
|
|
WO2025090427A1
(en)
|
2023-10-23 |
2025-05-01 |
University Of Rochester |
Glial-targeted relief of hyperexcitability in neurodegenerative diseases
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025155753A2
(en)
|
2024-01-17 |
2025-07-24 |
Renagade Therapeutics Management Inc. |
Improved gene editing system, guides, and methods
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025184567A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025202473A1
(en)
|
2024-03-28 |
2025-10-02 |
Revvity Discovery Limited |
A nucleic acid deaminase, a base editor and uses thereof
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025240946A1
(en)
|
2024-05-17 |
2025-11-20 |
Intellia Therapeutics, Inc. |
Lipid nanoparticles and lipid nanoparticle compositions
|
|
WO2025250454A1
(en)
|
2024-05-28 |
2025-12-04 |
University Of Rochester |
Adeno-associated viruses evolved to specifically target human glial progenitor cells in vivo
|
|
WO2025255308A1
(en)
|
2024-06-07 |
2025-12-11 |
Intellia Therapeutics, Inc. |
Cd8 co-receptor chimeric polypeptides in tcr cell therapy
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|